Use of nifurtimox for treating giardiasis

A technology of nifurtimox and disease, applied in the direction of resistance to vector-borne diseases, medical preparations containing active ingredients, drug combinations, etc., can solve problems such as treatment failure

Inactive Publication Date: 2011-06-01
BAYER IP GMBH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Many of these types of active substances have been used to treat giardiasis for a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of nifurtimox for treating giardiasis
  • Use of nifurtimox for treating giardiasis
  • Use of nifurtimox for treating giardiasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Embodiment 1 (liquid preparation):

[0101] Suspension with the following drugs in 100 ml of glycerol formaldehyde / glycerol macrogol ricinoleate (Cremophor® EL) / water with a mixing ratio of 1:10:

[0102] ● 500 mg nifurtimox

[0103] ● 1000 mg nifurtimox

Embodiment 2

[0104] Embodiment 2 (liquid preparation):

[0105] Suspension with the following drugs in 100 ml of Cremophor® EL / water with a mixing ratio of 1:5

[0106] ● 500 mg nifurtimox

[0107] ● 1000 mg nifurtimox

Embodiment 3

[0108] Embodiment 3 (solid preparation)

[0109] The active substance is filled in powder form into gelatin capsules in the following amounts:

[0110] ● 250 mg nifurtimox

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the use of nifurtimox for the treatment of giardiasis, particularly in dogs and cats.

Description

technical field [0001] The present invention relates to the use of nifurtimox for the treatment of Giardiose, especially in dogs and cats. Background technique [0002] The efficacy of nitroheterocyclic compounds against protozoan diseases is known (1). [0003] Protozoa include monokaryotic organisms whose basic structure is eukaryotic cells. However, a more detailed taxonomy reveals large differences in origin, morphology, and biochemical metabolism among lines, classes, genera, and species. This is why, depending on their target and active ingredient, chemicals generally do not act equally well on all protozoa, but only on specific groups of protozoa (2, 3, 4). [0004] So far, nifurtimox has only been described to have efficacy against protozoan species of the genus Trypanosoma, such as Trypanosoma brucei and Trypanosoma cruzi (5). Trypanosomes have flagella that originate from a basal body ("tricola basal body"), to which they attach to produce a corrugated membrane....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/541A61K38/15A61P33/02
CPCA61K38/15A61K31/541A61K9/0095A61K9/4841A61K9/10A61P33/00A61P33/02A61P33/10Y02A50/30A61K2300/00
Inventor G.格雷夫A.哈德T.巴赫G.佩特里E-M.克鲁德瓦根
Owner BAYER IP GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products